Denufosol
Alternative Names: Denufosol tetrasodium; INS 37217; INS 37217 ophthalmic; INS37217 RespiratoryLatest Information Update: 24 Oct 2021
At a glance
- Originator Inspire Pharmaceuticals
- Class Decongestants; Expectorants; Eye disorder therapies; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Purinoceptor P2U agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis; Dry eyes; Perennial allergic rhinitis; Retinal disorders; Retinal oedema; Sinusitis
Most Recent Events
- 18 Feb 2011 Discontinued - Phase-II for Cystic fibrosis in USA (Inhalation)
- 18 Feb 2011 Discontinued - Phase-III for Cystic fibrosis in Australia (Inhalation)
- 18 Feb 2011 Discontinued - Phase-III for Cystic fibrosis in Canada (Inhalation)